EuroPCR 2020 | Is Renal Denervation Coming Back to Life?

Additional analyses from the Global SYMPLICITY Registry and the RADIANCE-HTN SOLO trial, presented virtually at EuroPCR 2020, can contribute to the comeback of renal denervation as another alternative for patients with uncontrolled hypertension.

The 3-year results from the SYMPLICITY registry showed significant and durable reductions in blood pressure regardless of how many medications patients were taking.


Additionally, the patients from the RADIANCE-HTN SOLO trial (which was sham-controlled) who underwent denervation also showed sustained drops in blood pressure.


Renal denervation can act on hypertension independent of patient adherence and that makes it completely different from all other strategies.

The Global SYMPLICITY Registry, with over 2800 patients treated with the Symplicity Flex or Spyral radiofrequency catheter, showed an average drop of 16.7 mmHg in office systolic blood pressure and 9.2 mmHg in outpatient 24-hour systolic blood pressure consistently for up to 3 years.

Read also: Anesthetic Modes and Their Impact on Elective Endoprostheses.

Adverse events such as death (5.5%), cardiovascular death (2.9%), stroke (4.5%), and hospitalization for heart failure (4%) are within the expected ranges for this high-risk population. On the other hand, the rate for new renal artery stenosis ≥70% was just 0.3%.

This study confirms the long-term efficacy and safety of the procedure.

Original title: Three-Year Safety and Efficacy in the Global SYMPLICITY Registry: Impact of Anti-Hypertensive Medication Burden on Blood Pressure Reduction.

Reference: Mahfoud F. Presented virtually at EuroPCR 2020.

Would you like to receive a weekly summary of the most recent scientific articles?

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.